Icon expands clinical trial technology platform

TriMed Staff | | Health Imaging | Oncology Imaging
Medical imaging core lab services provider Icon Medical Imaging has expanded its technology platform to expedite oncology clinical trials, incorporating RECIST (Response Evaluation Criteria In Solid Tumors) 1.1 evaluation criteria to its ICOSpeedRead system.

The ICOSpeedRead supports the review of medical images in oncology clinical trials, said the Dublin-based company. With the addition of RECIST, criteria for studies with imaging endpoints, such as progression-free survival and tumor response will be applied.

TriMed Staff

Related Content

MRI guidance significantly reduces radiotherapy side effects compared to CT
Interventional procedure often as effective as surgery for difficult-to-treat liver cancer
AI tumor volume estimations could improve prostate cancer treatment strategies
MRI could be 'powerful tool' for guiding surgery decisions in patients with rectal cancer
Breast cancer only visible via MRI is often less aggressive
Breast cancer rates are on the rise, new report reveals

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.